Welcome to ProbeChem!Global Supplier of Chemical Probes, Inhibitors & Agonists.
Chemical Structure : Ixazomib
CAS No.: 1072833-77-2
Catalog No.: PC-42596Not For Human Use, Lab Use Only.
Ixazomib (MLN2238) is a potent, selective, orally bioavailable proteasome inhibitor with IC50 of 3.4 nM.
| Packing | Price | Stock | Quantity |
|---|---|---|---|
| 10 mg | $88 | In stock | |
| 25 mg | $138 | In stock | |
| 50 mg | $228 | In stock | |
| 100 mg | Get quote |
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Ixazomib (MLN2238) is a potent, selective, orally bioavailable proteasome inhibitor with IC50 of 3.4 nM.
Ixazomib binds to and inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with Ki of 0.93 nM, weakly inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites (IC50 of 31 and 3,500 n M).
Ixazomib inhibits growth and induces apoptosis in MM cells.
Ixazomib shows improved antitumor activity in models of lymphoma compared with bortezomib.
| M.Wt | 361.0287 | |
| Formula | C14H19BCl2N2O4 | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
DMSO: ≥ 28 mg/mL |
|
| Chemical Name/SMILES |
Boronic acid, B-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]- |
|
1. Kupperman E, et al. Cancer Res. 2010 Mar 1;70(5):1970-80.
2. Chauhan D, et al. Clin Cancer Res. 2011 Aug 15;17(16):5311-21.
3. Lee EC, et al. Clin Cancer Res. 2011 Dec 1;17(23):7313-23.
4. Tian Z, et al. Blood. 2012 Nov 8;120(19):3958-67.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright
